Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th

Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing therapies for hard-to-treat cancers, particularly through Focal Adhesion Kinase (FAK) inhibitors [5] - The company is targeting fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF) [5] Recent Developments - Dr. Chris Burns, CEO and Managing Director, will present at the Life Sciences Virtual Investor Forum on December 11, 2025 [1] - The company is available for one-on-one meetings on December 11, 15, and 16, after 3 PM ET [2] - Top-line data from the ACCENT pancreatic cancer trial indicates that narmafotinib, when dosed in combination with chemotherapy, shows superior efficacy compared to chemotherapy alone [8] - The AMPLICITY Phase 1b pancreatic cancer trial commenced dosing in September 2025 [8] - The company has received Fast Track Designation and Orphan Drug Designation for its pancreatic cancer treatment [8] - Promising preclinical data suggests potential expansion opportunities in pancreatic cancer when combined with kRAS inhibitors [8] - Positive preclinical data has also been reported in ovarian cancer, indicating an additional therapeutic opportunity [8] Event Information - The Life Sciences Virtual Investor Forum will be an interactive online event allowing real-time questions from investors [2][3] - Investors are encouraged to pre-register and conduct an online system check to facilitate participation [3] Investor Engagement - Virtual Investor Conferences (VIC) provides a platform for publicly traded companies to present directly to investors, enhancing investor access and engagement [6][7]